HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HCW-9218’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HCW-9218 is under development for the treatment of metastatic pancreatic cancer, other solid tumors including refractory breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, ageing and idiopathic pulmonary fibrosis, liver cancer, and non-alcoholic fatty liver disease (NAFLD). It is administered through subcutaneous route. The drug candidate is a heterodimeric, bifunctional fusion protein complex TGF-beta combined with IL-15 and is developed based on TOBI (Tissue factor based fusion) platform which acts by targeting transforming growth factor beta (TGF-beta).
HCW Biologics overview
HCW Biologics is a developer of immunotherapy platforms to activate the immune system in order to disrupt the links between aging and disease. HCW Biologics is headquartered in Miramar, Florida, the US.
For a complete picture of HCW-9218’s drug-specific PTSR and LoA scores, buy the report here.